Sort   by:  
 Page size 
ProteomicsqChIP-MS reveals the local chromatin composition by label-free quantitative proteomics
Chromatin immunoprecipitation (ChIP) has been a cornerstone for epigenetic analyses over the last decades, but even coupled to sequencing approaches (ChIP-seq), it is ultimately limited to one protein at a time. In a complementary effort, we here combine ChIP with label-free quantitative mass spectr...
ORGANISM(S): Homo sapiens (Human) 
2026-04-03 | PXD076520 | Pride
ProteomicsSignalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)
Alternative lengthening of telomeres (ALT) supports telomere maintenance and replicative immortality in around 10-15% of cancers, thus representing a compelling target for therapy.To identify anti-cancer drugs that can be repurposed as ALT-centered therapies, we performed for a compound library scre...
ORGANISM(S): Homo sapiens (Human) 
2023-02-20 | PXD037501 | Pride
Telomeres Alt Ponatinib Sarcoma Jun 
ProteomicsNovel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...
ORGANISM(S): Homo sapiens (Human) 
2020-09-28 | PXD021001 | Pride
Silac Proteasome Selinexor Quantitative proteomics Liposarcoma 
ProteomicsNovel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...
ORGANISM(S): Homo sapiens (Human) 
2020-09-28 | PXD020906 | Pride
Carfilzomib Silac Quantitative mass spectrometry Liposarcoma Proteasome 
ProteomicsASCL1: a pioneer factor that induces subtype switching and characterizes adrenergic neuroblastoma
Neuroblastoma is an embryonic malignancy originating from early nerve cells. Neuroblastoma retains plasticity, interconverting between the mesenchymal (MES) and adrenergic (ADRN) states, which are controlled by different sets of transcription factors forming the core regulatory circuit (CRC). Howeve...
ORGANISM(S): Homo sapiens (Human) 
2023-12-08 | PXD037670 | Pride
Ascl1 Subtype switching Neuroblastoma Pioneer factor Core regulatory circuit 
ProteomicsSystematic analysis of intronic microRNAs reveals cooperativity within the multi-component FTX locus to promote colon cancer development
Approximately half of all microRNAs reside within intronic regions and are often co-transcribed with their host genes. However, most studies on intronic microRNAs focus on individual microRNAs, and conversely most studies on protein-coding and non-coding genes frequently ignore any intron-derived mi...
ORGANISM(S): Homo sapiens (Human) 
2021-01-05 | PXD021823 | Pride
Micrornas A-to-i editing Colon cancer Long noncoding rna Post-transcriptional regulation 
ProteomicsE4F1 and ZNF148 are transcriptional activators of the A57C and wildtype TERT promoter
Point mutations within the TERT promoter are the most common recurrent somatic non-coding mutation identified across different cancer types, including glioblastoma, melanoma, hepatocellular carcinoma and bladder cancer. They are most abundant at C146T and C124T and more rare at A57C, with the latter...
ORGANISM(S): Homo sapiens (Human) 
2023-11-04 | PXD037776 | Pride
Tert promoter mutations Znf148 E4f1 Telomerase 
ProteomicsMELK mediates the stability of EZH2 throught site-specific phosphorylation in extranodal natural killer/T-cell lymphoma
Oncogenic EZH2 is overexpressed and extensively involved in the pathophysiology of different cancers including extranodal natural killer/T-cell lymphoma (NKTL). However, the mechanisms regarding EZH2 upregulation is poorly understood, and it still remains untargetable in NKTL. In this study, we exam...
ORGANISM(S): Homo sapiens (Human) 
2019-08-26 | PXD015008 | Pride
Melk Silac Ubiquitination Phosphorylation Extranodal natural killer/t-cell lymphoma (nktl) Ezh2 
ProteomicsLong non-coding RNA PLUM controls PRC2-mediated H3K27 methylation in multiple myeloma to promote chemoresistance
Multiple myeloma (MM) ranks the second most prevalent haematological malignancy globally. Despite advancements in managing MM, it remains incurable due to the high genetic heterogeneity leading to treatment resistance and disease severity. One key drug resistance associated signalling pathway often ...
ORGANISM(S): Homo sapiens (Human) 
2025-06-23 | PXD054586 | Pride
Non-coding rna Prc2 Plum Ezh2 Multiple myeloma Chemoresistance 
ProteomicsThe RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
Mutations in cancer are due in part to DNA cytosine deamination by APOBEC3B (A3B). While low in healthy tissues, A3B expression and activity are elevated in tumors and further increase in metastases. However, molecular mechanisms responsible for A3B transcriptional regulation are poorly understood. ...
ORGANISM(S): Homo sapiens (Human) 
2020-10-19 | PXD020473 | Pride
Cancer Silac Dna pull-down Polyoma virus t antigen Apobec3b 
Sort   by:  
 Page size